Who should not take Retatrutide?
Documented caution flags for Retatrutide include history of medullary thyroid carcinoma or MEN-2 and pancreatitis history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Retatrutide is limited.
Documented caution flags for Retatrutide
- History of medullary thyroid carcinoma or MEN-2
- Pancreatitis history
- Pregnancy / nursing
Reported side effects to weigh
- Nausea (especially first 2 weeks of each titration step)
- Vomiting
- Constipation or diarrhea
- Fatigue / lethargy
References
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — Jastreboff AM et al., NEJM, 2023
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA — Rosenstock et al., Lancet, 2023
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Sanyal et al., Nature Medicine, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Retatrutide
Full Retatrutide breakdownRetatrutide what it's used forRetatrutide side effectsRetatrutide how to take itRetatrutide mistakes to avoidRetatrutide half-lifeRetatrutide how long to workRetatrutide legal statusRetatrutide how it worksmazdutide vs retatrutidecagrilintide vs retatrutideretatrutide vs tirzepatidesemaglutide vs retatrutideAsk the AI Coach
Last updated 2026-06-15.